Cell Therapy Breakthrough Offers Hope for Liver Transplant Patients to Ditch Lifelong Drugs
Updated
Updated · BIOENGINEER.ORG · Apr 17
Cell Therapy Breakthrough Offers Hope for Liver Transplant Patients to Ditch Lifelong Drugs
5 articles · Updated · BIOENGINEER.ORG · Apr 17
Researchers at the University of Pittsburgh and UPMC have successfully used donor-derived regulatory dendritic cells to help liver transplant patients avoid lifelong immunosuppressive drugs.
In a small clinical trial, 4 out of 13 living-donor liver transplant recipients were able to discontinue immunosuppressants without organ rejection, some for over three years.
This approach could reduce the risks associated with long-term immunosuppression and marks a significant step toward immune tolerance in organ transplantation.
Could this immune-calming therapy be used for kidney or heart transplants in the future?
Can this therapy be adapted for organs from deceased donors, not just living ones?
Is cell therapy the future, or will 3D-printed organs make immunosuppression obsolete?
How do these special 'teacher' cells stop the body from rejecting a new donor organ?
Why can some transplant patients now stop medication while others still need it for life?
What is the true cost of this new cell therapy versus a lifetime of anti-rejection drugs?
Transforming Autoimmune Liver Disease: Birmingham’s Treg Therapy and the £3.83M Wellcome Discovery Award
Overview
In early 2026, the University of Birmingham received a £3.83 million Wellcome Discovery Award to lead an international effort developing Treg cell therapies for autoimmune liver diseases. This builds on the 2025 AUTUMN trial, which showed that patients' own regulatory T cells can safely target the liver, reduce immune rejection, and potentially allow reduced use of harmful immunosuppressive drugs. The therapy, based on the 1995 discovery of Tregs, offers a precise immune reprogramming approach that could improve patient outcomes and lower healthcare costs. However, challenges remain in manufacturing, long-term cell stability, and ethical considerations, especially as advanced CAR-Treg trials expand to other autoimmune diseases.